Atara Biotherapeutics is a leader in allogeneic T-cell therapy, with the most advanced clinical research program in the space. Our commitment is to make every effort to support patients in need of treatment options.

Our CTL immunotherapy platform has broad applicability across a variety of disease states and we are actively studying potential product candidates in multiple clinical trials to treat a variety of cancers, certain autoimmune and severe viral infectious diseases. We have designed all our clinical studies to specifically evaluate the potential of our investigational treatments in a well-defined cohort of patients with eligibility criteria that allow for appropriate assessment of safety and clinical effect. If you are interested in learning more about our ongoing clinical trials, please contact us at

For our more advanced programs in PTLD and CMV that have completed Ph 2, we recognize our planned Ph 3 trials will not be available to all patients who have life threatening diseases and no satisfactory treatment alternatives. For these patients, we have expanded access programs for PTLD (and EBV + tumors in general), and CMV disease. To learn more about these programs, please contact us at

As a general approach, for all our investigational product candidates, availability of these therapies is restricted to our ongoing clinical trials so that we can gather the appropriate data on their safety and efficacy in their respective patient populations. However, we recognize there may be instances where there is a significant patient need that we have not anticipated or encountered. If you would like to discuss availability of investigational drug product for a specific patient in significant need, or if you have a specific research idea, please contact us at

ongoing clinical trials >